Moderna

Autoimmune Hepatitis Reported Following COVID-19 mRNA Vaccination

A peer-reviewed case report published yesterday in the journal Cureus discusses the first documented case of a reactivation of autoimmune hepatitis in remission following the administration of a COVID-19 vaccine. Nine previously published case studies have also reported cases of autoimmune hepatitis being diagnosed after the administration of a COVID-19 vaccine.

Read More »

Assessing the Safety of mRNA COVID-19 Vaccination in the Immunocompromised

In a research article published yesterday in Frontiers in Oncology, COVID-19 vaccine (Pfizer and Moderna) safety was evaluated in a population of 566 immunocompromised patients including those with hematological malignancies (131), solid tumors (191), immune-rheumatological diseases (86), and neurological disease (158) including multiple sclerosis and generalized myasthenia.

Read More »

COVID-19 Vaccine Outcomes in Dermatomyositis Patients

A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.

Read More »

Antibody Levels in Immunocompromised Patients after Second Dose of mRNA Vaccine

Researchers at Johns Hopkins tested antibody levels in patients at 1, 3, and 6 months after the second dose of an mRNA vaccine. Overall, 96% of patients had positive antibody titers 6 months after the second dose of an mRNA vaccine. Antibody responses decreased from 1 to 6 months, but remained above the threshold for “predicted neutralizing capacity” in the majority of patients.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.